NASDAQ:CSTL Castle Biosciences - CSTL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $22.16 +0.60 (+2.78%) (As of 03/23/2023 04:32 PM ET) Add Compare Share Share Today's Range$21.61▼$22.6450-Day Range$19.47▼$28.4952-Week Range$15.58▼$47.27Volume135,290 shsAverage Volume154,253 shsMarket Capitalization$589.01 millionP/E RatioN/ADividend YieldN/APrice Target$52.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Castle Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside134.7% Upside$52.00 Price TargetShort InterestHealthy3.24% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 2 Articles This WeekInsider TradingSelling Shares$597,542 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.96) to ($1.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.32 out of 5 starsMedical Sector258th out of 986 stocksMedical Laboratories Industry10th out of 26 stocks 3.5 Analyst's Opinion Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.00, Castle Biosciences has a forecasted upside of 134.7% from its current price of $22.16.Amount of Analyst CoverageCastle Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.24% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 25.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSTL. Previous Next 2.6 News and Social Media Coverage News SentimentCastle Biosciences has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Castle Biosciences this week, compared to 2 articles on an average week.Search Interest15 people have searched for CSTL on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $597,542.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions82.43% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Castle Biosciences are expected to grow in the coming year, from ($2.96) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is -8.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is -8.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Castle Biosciences (NASDAQ:CSTL) StockCastle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.Read More Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Stock News HeadlinesMarch 20, 2023 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) is largely controlled by institutional shareholders who own 85% of the companyMarch 18, 2023 | finance.yahoo.comLate-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort StudyMarch 23, 2023 | Weiss Ratings (Ad)Banking NightmareDuring and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …March 10, 2023 | finance.yahoo.comCastle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual MeetingMarch 8, 2023 | finance.yahoo.comRecommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous MedicineMarch 3, 2023 | benzinga.comCastle Biosciences Stock (NASDAQ:CSTL), Short Interest ReportMarch 3, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Castle Biosciences (CSTL)March 1, 2023 | finance.yahoo.comQ4 2022 Castle Biosciences Inc Earnings CallMarch 23, 2023 | Weiss Ratings (Ad)Banking NightmareDuring and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …March 1, 2023 | finanznachrichten.deCastle Biosciences Reports Fourth Quarter and Full-Year 2022 ResultsFebruary 27, 2023 | finance.yahoo.comIs Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?February 24, 2023 | finance.yahoo.comCastle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & InvestingFebruary 22, 2023 | finance.yahoo.comData Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck TumorsFebruary 9, 2023 | finance.yahoo.comProspective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current GuidelinesFebruary 7, 2023 | finance.yahoo.comCastle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023February 1, 2023 | finance.yahoo.comCastle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive YearJanuary 23, 2023 | wsj.comCastle Biosciences' Medical Director to Present at the Precision Medicine World Conference 2023January 23, 2023 | finance.yahoo.comCastle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023January 17, 2023 | benzinga.comData Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences' Skin Cancer Test PortfolioJanuary 17, 2023 | finance.yahoo.comData Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test PortfolioJanuary 8, 2023 | markets.businessinsider.comCastle Biosciences Expects 2022 Revenue To Meet Or Exceed Top End Of Guided RangeJanuary 8, 2023 | finance.yahoo.comCastle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 ResultsDecember 15, 2022 | seekingalpha.comCastle Biosciences: Potential To Re-Rate With Supportive Fundamentals, Technicals, Underlying MarketDecember 8, 2022 | forbes.comCastle BiosciencesNovember 22, 2022 | bizjournals.comPittsburgh lab receives pathology certificationNovember 21, 2022 | finance.yahoo.comCastle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical LaboratoryNovember 17, 2022 | finance.yahoo.comResearch Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Company Calendar Last Earnings11/07/2021Today3/23/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CSTL CUSIPN/A CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees342Year FoundedN/APrice Target and Rating Average Stock Price Forecast$52.00 High Stock Price Forecast$80.00 Low Stock Price Forecast$38.00 Forecasted Upside/Downside+133.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,140,000.00 Net Margins-48.99% Pretax Margin-50.28% Return on Equity-15.45% Return on Assets-13.92% Debt Debt-to-Equity RatioN/A Current Ratio8.09 Quick Ratio7.98 Sales & Book Value Annual Sales$137.04 million Price / Sales4.31 Cash FlowN/A Price / Cash FlowN/A Book Value$15.15 per share Price / Book1.47Miscellaneous Outstanding Shares26,580,000Free Float24,636,000Market Cap$591.14 million OptionableNot Optionable Beta1.05 Key ExecutivesDerek J. MaetzoldPresident, Chief Executive Officer & DirectorKristen M. OelschlagerChief Operating OfficerFranklin Michael StokesChief Financial OfficerRobert W. CookSenior Vice President-Research & DevelopmentMatthew GoldbergMedical DirectorKey CompetitorsProgenityNASDAQ:PROGCareDxNASDAQ:CDNAInvitaeNYSE:NVTAFulgent GeneticsNASDAQ:FLGTCelcuityNASDAQ:CELCView All CompetitorsInsiders & InstitutionsDerek J MaetzoldSold 2,792 sharesTotal: $68,990.32 ($24.71/share)Daniel BradburySold 11,349 sharesTotal: $264,431.70 ($23.30/share)Voya Investment Management LLCBought 39,608 shares on 2/28/2023Ownership: 0.397%First Light Asset Management LLCSold 1,620 shares on 2/15/2023Ownership: 0.613%Capital Impact Advisors LLCBought 997 shares on 2/15/2023Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions CSTL Stock - Frequently Asked Questions Should I buy or sell Castle Biosciences stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares. View CSTL analyst ratings or view top-rated stocks. What is Castle Biosciences' stock price forecast for 2023? 6 Wall Street research analysts have issued 1 year price objectives for Castle Biosciences' shares. Their CSTL share price forecasts range from $38.00 to $80.00. On average, they anticipate the company's share price to reach $52.00 in the next year. This suggests a possible upside of 133.8% from the stock's current price. View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts. How have CSTL shares performed in 2023? Castle Biosciences' stock was trading at $23.54 on January 1st, 2023. Since then, CSTL shares have decreased by 5.5% and is now trading at $22.24. View the best growth stocks for 2023 here. Are investors shorting Castle Biosciences? Castle Biosciences saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 862,000 shares, a drop of 25.0% from the February 13th total of 1,150,000 shares. Based on an average daily volume of 154,900 shares, the short-interest ratio is presently 5.6 days. View Castle Biosciences' Short Interest. When is Castle Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our CSTL earnings forecast. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) posted its earnings results on Sunday, November, 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.13. The firm had revenue of $23.48 million for the quarter, compared to the consensus estimate of $23.66 million. Castle Biosciences had a negative trailing twelve-month return on equity of 15.45% and a negative net margin of 48.99%. During the same period last year, the firm posted ($0.23) earnings per share. What ETFs hold Castle Biosciences' stock? ETFs with the largest weight of Castle Biosciences (NASDAQ:CSTL) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), First Trust Innovation Leaders ETF (ILDR), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), iShares U.S. Healthcare Providers ETF (IHF), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB). What guidance has Castle Biosciences issued on next quarter's earnings? Castle Biosciences issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $170.00 million-$180.00 million, compared to the consensus revenue estimate of $168.34 million. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC). When did Castle Biosciences IPO? (CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. What is Castle Biosciences' stock symbol? Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL." Who are Castle Biosciences' major shareholders? Castle Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Granahan Investment Management LLC (3.96%), Millennium Management LLC (3.47%), Principal Financial Group Inc. (3.46%), Kornitzer Capital Management Inc. KS (2.72%), Portolan Capital Management LLC (2.22%) and Palisade Capital Management LLC NJ (2.09%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Bernhard E Spiess, Bonnie H Anderson, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Sofinnova Healthquest Partners, Tiffany Olson and Tobin W Juvenal. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Castle Biosciences' stock price today? One share of CSTL stock can currently be purchased for approximately $22.24. How much money does Castle Biosciences make? Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $591.14 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. How many employees does Castle Biosciences have? The company employs 342 workers across the globe. How can I contact Castle Biosciences? Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com. This page (NASDAQ:CSTL) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.